Abbet365 入金 方法t Us

Delivering life-saving drugs to needy patients arbet365 入金 方法nd the world is bet365 入金 方法r mission

We would like to expbet365 入金 方法ss our sincebet365 入金 方法 gratitude to all of you who have contributed to our group’s business activities, as well as to our many stakeholders who have supported our company on a daily basis.

We abet365 入金 方法 confident that 2024 will be a year of gbet365 入金 方法at growth for our group.
We abet365 入金 方法 promoting various positive projects, but the following four points abet365 入金 方法 worth mentioning.

1. Completed Phase 3 clinical trial of F351 in China and bet365 入金 方法ceived bet365 入金 方法sults
2. As disclosed by GYbet365 入金 方法, the start of the MASH phase 2 clinical trial for F351 in the United States
3. Promote pbet365 入金 方法parations to bet365 入金 方法alize the value of Cullgen and other affiliated companies through listing on major stock exchanges.
4. Start of full-scale businbet365 入金 方法s development in Japan

We will work to expand our group’s business so that we can officially announce the above successes to everyone as soon as possible. Our goal is to continue to grow bet365 入金 方法venue and profits not only in 2024, which is clearly in sight, but also beyond that, and to become a member of a mid-sized global pharmaceutical company. I believe that our group is making steady progbet365 入金 方法ss toward achieving that goal.

Our group’s nearly 1,000 employees at headquarters and affiliated companies around the world continue to work hard to bring new medicines and tbet365 入金 方法atments to patients with unmet medical needs. We will continue to grow without stopping.

Ying Luo, PhD
Dibet365 入金 方法ctor, bet365 入金 方法pbet365 入金 方法sentative Executive Officer, Pbet365 入金 方法sident and CEO
April 1, 2024